Nathan Weinstein
Stock Analyst at Aegis Capital
(0.26)
# 4,393
Out of 5,113 analysts
61
Total ratings
13.33%
Success rate
-26.26%
Average return
Main Sectors:
Stocks Rated by Nathan Weinstein
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EVGN Evogene | Maintains: Buy | $100 → $80 | $1.02 | +7,743.91% | 2 | Sep 12, 2022 | |
| DRIO DarioHealth | Maintains: Buy | $400 → $300 | $11.54 | +2,499.65% | 6 | Aug 18, 2022 | |
| VNRX VolitionRx | Maintains: Buy | $9 → $6 | $0.26 | +2,243.75% | 5 | Aug 15, 2022 | |
| IMUX Immunic | Maintains: Buy | $40 → $35 | $0.57 | +6,008.20% | 2 | Aug 8, 2022 | |
| STXS Stereotaxis | Initiates: Buy | $6 | $2.34 | +156.41% | 1 | Jul 12, 2022 | |
| ORMP Oramed Pharmaceuticals | Maintains: Buy | $35 → $30 | $2.93 | +923.89% | 5 | May 16, 2022 | |
| TRVI Trevi Therapeutics | Initiates: Buy | $10 | $13.01 | -23.14% | 1 | Mar 29, 2022 | |
| MDWD MediWound | Maintains: Buy | $63 → $49 | $18.77 | +161.05% | 4 | Mar 21, 2022 | |
| ENVB Enveric Biosciences | Downgrades: Hold | $63,000 → $1,800 | $5.08 | +35,333.07% | 2 | Mar 8, 2022 | |
| CING Cingulate | Initiates: Buy | $2,160 | $3.97 | +54,308.06% | 1 | Jan 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $120 | $1.89 | +6,249.21% | 1 | Dec 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 → $10 | $1.02 | +880.39% | 2 | Nov 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $180 → $160 | $220.80 | -27.54% | 2 | Sep 22, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $60 → $56 | $25.39 | +120.56% | 2 | Sep 9, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $26 → $27 | $3.96 | +581.82% | 3 | Aug 17, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $40 → $35 | $0.63 | +5,482.14% | 4 | Jun 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $12 | $1.77 | +577.97% | 1 | Mar 22, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $75 | $13.01 | +476.48% | 1 | Jan 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $104 → $88 | $2.31 | +3,709.52% | 3 | Oct 19, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $180 | $0.78 | +23,042.20% | 1 | Oct 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $195 → $135 | $4.86 | +2,677.78% | 3 | Aug 3, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $14 | $5.97 | +134.51% | 1 | Jul 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $180 → $220 | $13.80 | +1,494.20% | 7 | May 4, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $8.5 | $3.30 | +157.58% | 1 | Mar 23, 2020 |
Evogene
Sep 12, 2022
Maintains: Buy
Price Target: $100 → $80
Current: $1.02
Upside: +7,743.91%
DarioHealth
Aug 18, 2022
Maintains: Buy
Price Target: $400 → $300
Current: $11.54
Upside: +2,499.65%
VolitionRx
Aug 15, 2022
Maintains: Buy
Price Target: $9 → $6
Current: $0.26
Upside: +2,243.75%
Immunic
Aug 8, 2022
Maintains: Buy
Price Target: $40 → $35
Current: $0.57
Upside: +6,008.20%
Stereotaxis
Jul 12, 2022
Initiates: Buy
Price Target: $6
Current: $2.34
Upside: +156.41%
Oramed Pharmaceuticals
May 16, 2022
Maintains: Buy
Price Target: $35 → $30
Current: $2.93
Upside: +923.89%
Trevi Therapeutics
Mar 29, 2022
Initiates: Buy
Price Target: $10
Current: $13.01
Upside: -23.14%
MediWound
Mar 21, 2022
Maintains: Buy
Price Target: $63 → $49
Current: $18.77
Upside: +161.05%
Enveric Biosciences
Mar 8, 2022
Downgrades: Hold
Price Target: $63,000 → $1,800
Current: $5.08
Upside: +35,333.07%
Cingulate
Jan 11, 2022
Initiates: Buy
Price Target: $2,160
Current: $3.97
Upside: +54,308.06%
Dec 7, 2021
Initiates: Buy
Price Target: $120
Current: $1.89
Upside: +6,249.21%
Nov 1, 2021
Maintains: Buy
Price Target: $9 → $10
Current: $1.02
Upside: +880.39%
Sep 22, 2021
Maintains: Buy
Price Target: $180 → $160
Current: $220.80
Upside: -27.54%
Sep 9, 2021
Maintains: Buy
Price Target: $60 → $56
Current: $25.39
Upside: +120.56%
Aug 17, 2021
Maintains: Buy
Price Target: $26 → $27
Current: $3.96
Upside: +581.82%
Jun 7, 2021
Maintains: Buy
Price Target: $40 → $35
Current: $0.63
Upside: +5,482.14%
Mar 22, 2021
Initiates: Buy
Price Target: $12
Current: $1.77
Upside: +577.97%
Jan 26, 2021
Initiates: Buy
Price Target: $75
Current: $13.01
Upside: +476.48%
Oct 19, 2020
Maintains: Buy
Price Target: $104 → $88
Current: $2.31
Upside: +3,709.52%
Oct 8, 2020
Initiates: Buy
Price Target: $180
Current: $0.78
Upside: +23,042.20%
Aug 3, 2020
Maintains: Buy
Price Target: $195 → $135
Current: $4.86
Upside: +2,677.78%
Jul 13, 2020
Initiates: Buy
Price Target: $14
Current: $5.97
Upside: +134.51%
May 4, 2020
Maintains: Buy
Price Target: $180 → $220
Current: $13.80
Upside: +1,494.20%
Mar 23, 2020
Initiates: Buy
Price Target: $8.5
Current: $3.30
Upside: +157.58%